Literature DB >> 33520543

COVID-19 Infection and Acute Pulmonary Embolism in an Adolescent Female With Sickle Cell Disease.

Sushma Kasinathan1, Hasina Mohammad Ashraf1, Sheera Minkowitz1, Adebayo Adeyinka1, Keneisha Bailey-Correa1.   

Abstract

A previously healthy 20-year-old female presented to the emergency room in April 2020 with complaints of shortness of breath, chest pain, and cough. She was diagnosed with coronavirus disease 2019 (COVID-19) infection and pulmonary embolism (PE). Workup for anemia led to the diagnosis of sickle cell disease (SCD). Patients diagnosed with COVID-19 are at an increased risk for the development of PE and venous thromboembolism (VTE). Anticoagulation prophylaxis and escalation to treatment dosing are recommended in patients admitted with moderate to severe symptoms of COVID-19. PE and VTE are relatively uncommon in the pediatric and adolescent population. Most commonly, patients are diagnosed with thrombophilia or have an underlying hypercoagulable state such as with SCD. Also, symptoms of COVID-19 infection, acute chest syndrome (ACS), and PE can have overlapping features. In this report, we present a case of a late adolescent female with SCD, who was diagnosed with COVID-19, and whose condition was complicated with PE.
Copyright © 2020, Kasinathan et al.

Entities:  

Keywords:  covid-19; pulmonary embolism; sickle cell disease; sickle cell hbsc

Year:  2020        PMID: 33520543      PMCID: PMC7840446          DOI: 10.7759/cureus.12348

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  2 in total

1.  COVID-19 and venous thromboembolism risk in patients with sickle cell disease.

Authors:  Ashima Singh; Amanda M Brandow; Ted Wun; Arun S Shet
Journal:  Blood Adv       Date:  2022-08-09

Review 2.  Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature.

Authors:  Wouter S Hoogenboom; Tharun T Alamuri; Daniel M McMahon; Nino Balanchivadze; Vrushali Dabak; William B Mitchell; Kerry B Morrone; Deepa Manwani; Tim Q Duong
Journal:  Blood Rev       Date:  2021-11-20       Impact factor: 10.626

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.